{"id":560373,"date":"2026-07-01T18:00:00","date_gmt":"2026-07-01T16:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/retatrutid-and-the-triumph-program-the-triple-agonist-on-the-horizon\/"},"modified":"2026-07-09T18:05:00","modified_gmt":"2026-07-09T16:05:00","slug":"retatrutid-and-the-triumph-program-the-triple-agonist-on-the-horizon","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/retatrutid-and-the-triumph-program-the-triple-agonist-on-the-horizon\/","title":{"rendered":"Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon"},"content":{"rendered":"\n

Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP\/GLP-1 agonist tirzepatide and on to a triple agonist. <\/em>Retatrutide (LY3437943) is a single molecule that activates three receptors simultaneously\u2014those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This expansion follows a plausible logic: with each additional mechanism of action, the average weight loss in the studies increased\u2014from GLP-1 alone, through GLP-1 plus GIP, to the triple combination. Retatrutide is the most advanced representative of this new class to date and attracted significant attention in 2025\/2026 with the first Phase 3 results from the TRIUMPH program.<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP\/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cardiometabolism","footnotes":""},"category":[11548,11359,11508,11384,11297,11388,11460,11503],"tags":[95235,17444,72410,95237,95236],"powerkit_post_featured":[],"class_list":["post-560373","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-cardiology","category-education","category-endocrinology-and-diabetology","category-general-internal-medicine","category-nutrition","category-prevention-and-health-care","category-studies","tag-retatrutid","tag-semaglutide-en-2","tag-tirzepatide","tag-triple-agonist","tag-triumph","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-20 04:44:52","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":560506,"slug":"le-retatrutide-et-le-programme-triumph-le-triple-agoniste-en-passe-detre-commercialise","post_title":"Le Retatrutid et le programme TRIUMPH : le triple agoniste en passe de voir le jour","href":"https:\/\/medizinonline.com\/fr\/le-retatrutide-et-le-programme-triumph-le-triple-agoniste-en-passe-detre-commercialise\/"},"it_IT":{"locale":"it_IT","id":560867,"slug":"retatrutid-e-il-programma-triumph-il-triplo-agonista-in-fase-di-sviluppo","post_title":"Retatrutid e il programma TRIUMPH: il triplo agonista in fase di sviluppo","href":"https:\/\/medizinonline.com\/it\/retatrutid-e-il-programma-triumph-il-triplo-agonista-in-fase-di-sviluppo\/"},"pt_PT":{"locale":"pt_PT","id":560870,"slug":"o-retatrutid-e-o-programa-triumph-o-agonista-triplo-em-fase-de-desenvolvimento","post_title":"O Retatrutid e o programa TRIUMPH: o agonista triplo em fase de desenvolvimento","href":"https:\/\/medizinonline.com\/pt-pt\/o-retatrutid-e-o-programa-triumph-o-agonista-triplo-em-fase-de-desenvolvimento\/"},"es_ES":{"locale":"es_ES","id":560873,"slug":"retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha","post_title":"Retatrutid y el programa TRIUMPH: el agonista triple en marcha","href":"https:\/\/medizinonline.com\/es\/retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=560373"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560373\/revisions"}],"predecessor-version":[{"id":560375,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560373\/revisions\/560375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/560374"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=560373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=560373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=560373"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=560373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}